A CLINICAL CASE OF BULEVIRTIDE THERAPY FOR CHRONIC HDV-INFECTION

Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate antibodies to delta virus 35% [3]. urgency problem HDV infection also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug treatment hepatitis, was registered in Russia. Three randomized trials showed high virological, biochemical response, as well good tolerability safety. Objective – evaluate efficacy safety Bulevirtide infection. Material methods. A clinical case patient L. suffering from form receiving antiviral therapy presented. Results. demonstrated efficacy, evidenced development virological response during first 14 weeks decrease RNA undetectable level within 29. Conclusions. It necessary widely introduce patients with due